Alfa Cytology is pioneers in undertaking seprase (FAP)-targeted diagnostics focused on the discovery of new theranostic radiopharmaceuticals and the development of novel imaging agent.
Solutions
Online Inquiry
Autoimmune Diseases
Seprase or fibroblast activation protein (FAP) has become a key target for the treatment of autoimmune diseases during the past decade due to its contribution to generating inflammatory microenvironments. At Alfa Cytology, we aspire to pioneer seprase (FAP)-targeted therapies and diagnostics against a wide range of autoimmune diseases, leveraging advanced technology to cover all forms of therapy.
Introduction to Seprase (FAP)-Targeted Therapeutics for Autoimmune Diseases
Seprase (FAP) is a type II transmembrane protease with dipeptidyl peptidase and endopeptidase activities. Seprase (FAP) is expressed with the activation of fibroblasts in autoimmune inflammatory diseases, while it shows little or no expression in resting fibroblasts and most other cell types. Seprase (FAP) expression is upregulated during the activation of fibroblasts upon their exposure to inflammatory stimuli. The proposed action of seprase (FAP) constitutes a paracrine tumor-promoting and fibrotic activity of fibroblasts at sites of inflammation.
Fig. 1 68Ga-FAPI PET images before treatment (top row) and after treatment (bottom row) in patient with spondyloarthritis manifesting with sacroiliitis (upper left panel) and dactylitis of fourth finger. (Kuwert, T., et al. 2022)
Seprase (FAP)-Targeted Drug Development for Autoimmune Diseases
Extensive studies have documented the efficacy of seprase (FAP)-targeted drugs in the diagnosis and treatment of various autoimmune diseases. Below is a detailed list of available FAP-targeting drugs for different autoimmune diseases.
| Name | Indication | Effects | Phase |
| 68Ga-DOTA-FAPI-04 | Crohn's Disease | 68Ga-DOTA-FAPI-04 PET/CT is superior to CT small bowel imaging for lesion detection. | Preclinical |
| 68Ga-FAPI PET/CT | IgG4-Related Disease | 68Ga-FAPI PET/CT provides excellent detection of lesions in the pancreas, bile ducts, liver, lacrimal and salivary glands. | Preclinical |
| 68Ga-FAPI PET/CT | Rheumatoid Arthritis | The degree of joint wear was positively correlated with clinical progression of disease after receiving 68Ga-FAPI PET/CT injections. | Preclinical |
Disclaimer: Alfa Cytology focuses on providing preclinical research service. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
Moreover, Alfa Cytology is committed to discovering and developing seprase (FAP)-targeted therapies and diagnostics using cutting-edge technologies. Our platform provides integrated value-added solutions to address the unique challenges posed by different autoimmune conditions.
Diverse Autoimmune Diseases
Crohn's Disease
IgG4-Related Disease
Rheumatoid Arthritis
One-Stop Solutions
With a forward-thinking approach, we are developing several therapeutic strategies for seprase (FAP) across small molecule, antibody, and RDCs and are advocating research into innovative therapies.
Different research models and methodologies are incorporated during preclinical research services to investigate the efficacy, pharmacokinetics, and safety of seprase (FAP)-targeted drugs.
At Alfa Cytology, we believe that dedication is crucial in achieving our goals through collaborative efforts with customers. With our expertise in seprase (FAP) biology, autoimmune diseases, and drug development, we endeavor to develop customized solutions tailored to accelerate targeted seprase (FAP) therapeutics and diagnostics. Please contact us for more details regarding our services.
Reference
- Kuwert, T., et al. FAPI PET Opens a New Window to Understanding Immune-Mediated Inflammatory Diseases. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2022, 63(8): 1136-1137.
For research use only.